Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

PP405 is expected to work for hair regrowth by reactivating stem cells in hair follicles, with FDA approval anticipated in 2027-28. Users express both optimism and skepticism about its effectiveness and the lengthy approval process.

A user shares their 11-week progress using 1mg finasteride, 5% minoxidil twice daily, 0.8mm dermastamping every 10 days, occasional tretinoin, and ketoconazole shampoo for hair regrowth. They plan to continue the treatment for 9 months before considering a hair transplant.

The user reported noticeable hair improvement after four months using topical minoxidil, topical finasteride, microneedling, and ketoconazole shampoo. They plan to continue the regimen and are relieved by the progress.

GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.

Everychem's solution, similar to PP405, has mixed results for hair regrowth, with some users reporting improvements and others seeing no change or worsening hair loss. Users are sharing experiences and updates to determine its effectiveness.

A user is seeking advice on mixing GHK-cu/AHK-cu with minoxidil for hair loss treatment. They are asking for recommendations on the correct mixing ratios and any experiences with copper peptides.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

Hair loss without a white bulb may indicate mechanical damage, anagen effluvium, alopecia areata, or traction alopecia. Seeking a specialist is recommended, but access can be difficult in smaller areas.

The conversation discusses finding a PG-free solvent for dissolving RU58841 in the UK, with glycerin suggested as a potential alternative. Water is also mentioned as a possible option.

Kartogenin is being discussed as a potential topical treatment for hair growth. The conversation humorously notes its testing on animals like mice and rabbits.

The user experienced significant hair regrowth and increased confidence after 8 months using 5mg Minoxidil, 1.1mg Finasteride, and 1mg Biotin, with no side effects. The user received many compliments on their thicker hair and plans to get a haircut.

GHK-Cu injections led to unexpected temple hair growth for someone who had been using minoxidil and finasteride for over a decade. The user plans to continue using GHK-Cu and experiment with a DIY AHK-Cu serum.

RU58841 is being considered for hair maintenance by someone who can't tolerate finasteride. Alternatives like topical finasteride, dutasteride, and KX826 are also suggested.

Pyrilitamide (KX-826) did not show significant improvement in hair count compared to placebo after 6 months. It's unclear if it can maintain hair at baseline.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

The conversation discusses the potential of kintor pyrilutamide as a promising treatment for hair loss, with ongoing trials in various phases. There is skepticism due to delays in trial results, but the company is actively pursuing further trials.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

A user shared their positive experience with a hair transplant in Patna, using 1800 grafts to enhance their hairline and temple points. The procedure cost around Rs 85K, and the user is pleased with the natural-looking results.

User started Finasteride for hair loss and uses Toppik to cover bald spots. They wonder if Toppik's keratin fibers will block follicles and affect hair regrowth.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

A 27-year-old male experienced hair loss and dermatitis, which improved with tea tree oil and neem extract. He is considering using a 2% Ketoconazole solution for further treatment.

A user is considering adding RU58841 to their hair loss treatment regimen, seeking advice on trusted vendors, storage, and solution concentration. They currently use Finasteride and Dutasteride and are advised to store RU58841 in a fridge during hot months and that K&B and ethanol + PG solutions are equally effective, with irritation varying by individual.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

Concerns about the integrity of Dr. Melissa Toyos' marketing for Verteporfin treatment, suggesting photos may be digitally altered. Users express skepticism about the treatment's promotion and results.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

The conversation is about a user trying a 0.2% Alfatrafiol treatment for hair loss, combined with Kx826, Minoxidil, microneedling, and ketoconazole. The user reports reduced itching and discusses sourcing the treatment.

The user shared their hair regrowth progress using a combination of treatments including finasteride, dutasteride, minoxidil, tretinoin, Sulfogenz, KX-826, low-level laser therapy, and microneedling. They plan to continue medication for another year before considering a hair transplant, noting steady improvement but not major changes.